Abbott has announced late-breaking data from the Amulet LAA Occluder IDE trial, a multicentre, head-to-head study comparing the company’s Amplatzer Amulet left atrial appendage (LAA) occluder with the Watchman (Boston Scientific) device to treat patients with atrial fibrillation (AF) at an increased risk of stroke.
The results of the trial show Abbott’s Amulet device was superior for the primary endpoint of LAA closure and non-inferior for the primary endpoints of safety and effectiveness versus the comparator device.
The findings were presented in a late-breaking hot line session at the European Society of Cardiology’s 2021 congress (ESC 2021, 27–30 August, virtual) and simultaneously published in Circulation. The trial results supported the recent US approval of Amulet.
The LAA is a small pouch connected to the upper left chamber of the heart. For people with AF, the heart’s ability to effectively pump blood can be disrupted, allowing blood to pool and collect in the LAA causing an increased risk for clotting. If clots reach the blood stream, they can travel to the brain and cause a stroke.
Abbott’s Amulet device with Dual-Seal technology (a lobe to fill the body of the LAA and a disc to close off the opening into the LAA) offers immediate closure of the LAA, reducing the risk of stroke and immediately eliminates the need for blood-thinning medication following implant.
“Atrial fibrillation cases have increased in recent years as the world continues to age, making stroke risk more prevalent and resulting in higher usage of blood-thinning medication that can lead to bleeding and other complications,” said Dhanunjaya Lakkireddy, Kansas City Heart Rhythm Institute at HCA Midwest Health, Kansas City, USA, who served as principal investigator for the study. “Amulet demonstrated a clear benefit for people suffering from atrial fibrillation who are at risk of stroke and in need of LAA occlusion. The Amulet IDE trial data show that we can effectively treat these patients with Amulet and get them off blood thinners immediately following implantation.”
The Amulet IDE trial is the first multicentre, large-scale randomized study to compare Abbott’s Amulet device head-to-head with the Watchman device.
Results from the study demonstrated that Abbott’s Amulet Occluder with Dual-Seal technology:
- Was successfully implanted in 98.4% of patients compared to 96.4% of patients receiving the Watchman device.
- Demonstrated superiority for the primary endpoint of LAA closure compared to Watchman (98.9% vs. 96.8%, p (superiority) = 0.0025).
- Was non-inferior to the comparator device for the co-primary safety endpoint (a composite of procedure-related complications, all-cause death or major bleeding through 12 months) and co-primary effectiveness endpoint (a composite of ischaemic stroke or systemic embolism through 18 months).
Importantly for patients and their physicians, Amulet did not require the use of blood thinners for participants following implant in the study. Watchman patients were mostly (82%) discharged on anticoagulant therapy (warfarin plus aspirin). In contrast, only 20% of Amulet patients were discharged on anticoagulants, and most (75.7%) were discharged on dual antiplatelet therapy (clopidogrel plus aspirin).
“Now backed by the strength of the Amulet IDE data and the ability to immediately close the LAA, our Amulet device has the potential to change the way physicians approach LAA occlusion therapy,” said Michael Dale, senior vice president of Abbott’s structural heart business. “Offering immediate, superior LAA closure allows Americans living with atrial fibrillation to experience greater peace of mind against the worry of having a stroke without the need for blood-thinning medication immediately following the procedure.”
The Amplatzer Amulet LAA Occluder has been approved for use in more than 80 countries, including in Europe, Canada and Australia, since its initial CE mark approval in 2013.